Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2005 (Third Quarter of Fiscal 2005)
Business Overview: Cardinal Health operates four reportable segments: Pharmaceutical Distribution and Provider Services, Medical Products and Services, Pharmaceutical Technologies and Services, and Clinical Technologies and Services. The company is currently undergoing a significant business model transition in its Pharmaceutical Distribution segment and a global restructuring program.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Mar 31, 2005 | Nine Months Ended Mar 31, 2005 |
|---|---|---|
| Revenue | $19,103.0 | $55,453.6 |
| Gross Margin | $1,346.8 | $3,639.8 |
| Operating Earnings | $584.2 | $1,262.7 |
| Net Earnings | $365.7 | $793.0 |
| Diluted EPS | $0.84 | $1.82 |
| Cash from Operating Activities | N/A | $2,050.9 |
| Cash and Equivalents (Balance Sheet) | $1,549.5 | N/A |
| Total Debt (Short-term + Long-term) | $2,891.7 | N/A |
Note: Total Debt calculated as Notes payable/short-term borrowings ($81.6M) + Current portion of long-term obligations ($507.0M) + Long-term obligations ($2,303.1M).
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 17% ($2.7 billion) for the quarter and 15% ($7.3 billion) for the nine-month period compared to the prior year, driven by higher sales volume and acquisitions (notably Alaris).
- Profitability Decline: Despite revenue growth, Operating Earnings decreased 12% for the quarter and 28% for the nine-month period. Net Earnings declined 15% and 27%, respectively.
- Special Items Impact: The decline in earnings was significantly impacted by special items totaling $43.3 million for the quarter and $178.3 million for the nine months. These included $25.8 million in restructuring costs and $10.4 million in merger-related costs for the quarter.
- Asset Impairments: The company recorded $16.2 million in impairment charges for the quarter and $103.0 million for the nine months, compared to gains in the prior year. Significant impairments occurred in the Pharmaceutical Technologies and Services segment.
- Segment Performance:
- Pharmaceutical Distribution: Revenue up 18%, but operating earnings growth (8%) lagged due to reduced vendor margins and a shift to lower-margin bulk revenue.
- Clinical Technologies: Revenue up 32% (driven by Alaris acquisition), but operating earnings down 25% due to Pyxis product delays and competition.
- Pharmaceutical Technologies: Operating earnings down 28% due to regulatory issues and facility delays.
Guidance, Outlook, Risks, and Unusual Items
Restructuring and Outlook
The company is executing a global restructuring program expected to improve operating earnings by $125 million in fiscal 2005 and $200 million in fiscal 2006. The program involves rationalizing facilities and reducing the global workforce by approximately 4,200 employees. Estimated future costs for restructuring and integration are approximately $196.1 million.
Government Investigations and Legal Risks
- SEC and DOJ: The company is subject to a formal SEC investigation and a U.S. Attorney inquiry regarding revenue classification, cash discount recognition, and vitamin litigation recoveries. This has led to restatements of financial statements for fiscal years 2000-2004.
- Internal Review: The Audit Committee has completed its review of financial statement matters, resulting in disciplinary actions for several employees, including the resignation of the Controller. A separate Board committee is reviewing vitamin recovery accounting.
- Material Weaknesses: Management concluded that disclosure controls and procedures were not effective as of March 31, 2005, due to material weaknesses in internal controls over financial reporting, specifically regarding revenue recognition in the former Automation and Information Services segment.
- Other Litigation: Pending class action securities lawsuits, ERISA actions, and derivative suits related to the accounting issues and the Syncor acquisition. The company also faces an FTC investigation into potential anticompetitive practices.
Unusual Items
The company recorded a $16.4 million charge for latex litigation settlements. Additionally, the company recognized income from antitrust litigation settlements ($20.6 million for the nine months) which partially offset special item costs.
Investor Verification Checklist
- Restatement Scope: Verify if the SEC investigation or internal reviews will trigger further restatements of the current or prior period financial statements.
- Control Remediation: Assess the timeline and effectiveness of the company's plan to remediate the identified material weaknesses in internal controls.
- Pharmaceutical Margins: Monitor the progress of fee-for-service agreements with branded manufacturers to determine if the company can stabilize margins in its core distribution business.
- Restructuring Costs: Track actual cash outflows for the global restructuring program against the estimated $196.1 million future cost.
- Pyxis Performance: Evaluate the recovery of the Pyxis products business following the delays in the MedStation 3000 launch and increased competition.
- Liquidity Position: Confirm the company's ability to service debt and fund operations given the high level of special charges and ongoing legal costs.